{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:59:08Z","timestamp":1789469948954,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.maturitas.2018.03.013","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T20:23:17Z","timestamp":1522441397000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Hypertension in patients with type 2 diabetes mellitus: Targets and management"],"prefix":"10.1016","volume":"112","author":[{"given":"Dimitra I.","family":"Pavlou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-838X","authenticated-orcid":false,"given":"Michael","family":"Spartalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4451-8074","authenticated-orcid":false,"given":"Eleftherios","family":"Spartalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Vryonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-2534","authenticated-orcid":false,"given":"Nicholas","family":"Tentolouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-8870","authenticated-orcid":false,"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.maturitas.2018.03.013_bib0005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1161\/HYPERTENSIONAHA.111.00612","article-title":"Diabetes mellitus and vascular disease","volume":"61","author":"Sowers","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease: an update","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0015","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0002-8703(91)90432-H","article-title":"The epidemiology of impaired glucose tolerance and hypertension","volume":"121","author":"Kannel","year":"1991","journal-title":"Am. Heart J."},{"issue":"7258","key":"10.1016\/j.maturitas.2018.03.013_bib0020","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic BP with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36)","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0025","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/eurheartj\/ehm501","article-title":"Joint effects of history of hypertension at baseline and Type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease","volume":"28","author":"Hu","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0030","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/CIR.0000000000000034","article-title":"Type 1 diabetes mellitus and cardiovasculardisease: a scientific statement from the American Heart Association and American Diabetes Association","volume":"130","author":"de Ferranti","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0035","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dci15-0012","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc08-1881","article-title":"Insufficient control of BP and incident diabetes","volume":"32","author":"Izzo","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0045","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1096\/fj.01-0457fje","article-title":"Adipose angiotensinogen is involved in adipose tissue growth and BP regulation","volume":"15","author":"Massiera","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0050","doi-asserted-by":"crossref","first-page":"R943","DOI":"10.1152\/ajpregu.00265.2004","article-title":"Activation of the systemic and adipose renin angiotensin system in rats with diet-induced obesity and hypertension","volume":"287","author":"Boustany","year":"2004","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0055","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJM198708063170605","article-title":"Insulin resistance in essential hypertension","volume":"317","author":"Ferrannini","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0060","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.numecd.2007.05.002","article-title":"Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and BP in non-diabetic subjects: the GISIR database","volume":"18","author":"Bonora","year":"2008","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0065","first-page":"523","article-title":"Insulin action and insulin resistance in vascular endothelium","volume":"10","author":"Muniyappa","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrm1837","article-title":"Critical nodes in signalling pathways: insights into insulin action","volume":"7","author":"Taniguchi","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11892-003-0018-9","article-title":"Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium","volume":"3","author":"Vincent","year":"2003","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ajh\/hpv107","article-title":"Hypertension, diabetes type II, and their association: role of arterial stiffness","volume":"29","author":"Smulyan","year":"2016","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight BP control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0090","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive BP lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0095","first-page":"2560","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"58","author":"The ADVANCE Collaborative Group","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5\u20136","key":"10.1016\/j.maturitas.2018.03.013_bib0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/10641969909060982","article-title":"Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"21","author":"Fagard","year":"1999","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2337\/diacare.25.1.199","article-title":"Treatment of hypertension in adults with diabetes","volume":"25","author":"American Diabetes Association","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0110","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high BP","volume":"157","author":"Sixth Join National Committee","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0115","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high BP: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0120","first-page":"1462","article-title":"2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","author":"Mancia","year":"2007","journal-title":"Eur. Heart J."},{"issue":"27","key":"10.1016\/j.maturitas.2018.03.013_bib0125","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","author":"Mancia","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0130","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s001250050629","article-title":"Appropriate BP control in NIDT2 DM (ABCD) trial","volume":"39","author":"Schrier","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0135","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","article-title":"Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)","volume":"59","author":"Redon","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.2010.884","article-title":"Tight BP control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease","volume":"304","author":"Cooper-DeHoff","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0150","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"BP lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2018.03.013_bib0160","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20132013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0165","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for themanagement of arterial hypertension: the Task Force for the management ofarterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","year":"2013","journal-title":"J. Hypertens."},{"issue":"January (Suppl. 1)","key":"10.1016\/j.maturitas.2018.03.013_bib0170","first-page":"S4","article-title":"Standards of medical care in diabetes\u20132018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high BP in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0180","series-title":"Hypertension: The Clinical Management of Primary Hypertension in Adults. Update of Clinical Guidelines 18 and 34","year":"2011"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0185","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.0000150859.47929.8e","article-title":"Recommendations for BP measurement in humans and experimental animals: part 1: BP measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High BP Research","volume":"45","author":"Pickering","year":"2005","journal-title":"Hypertension"},{"issue":"Septembr (Suppl. 1)","key":"10.1016\/j.maturitas.2018.03.013_bib0190","first-page":"e24","article-title":"Home BP monitoring is better than office BP and ambulatory BP: update","volume":"34","author":"ISH","year":"2016","journal-title":"J. Hypertens."},{"issue":"May (5)","key":"10.1016\/j.maturitas.2018.03.013_bib0195","first-page":"453","article-title":"BP measurement anno 2016","volume":"30","author":"Staessen","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0200","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jacc.2016.01.037","article-title":"Morning home BP is a strong predictor of Coronary artery disease: the HONEST study","volume":"67","author":"Kario","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0205","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1681\/ASN.2005111200","article-title":"Racial differences in the prevalence of chronic kidney disease among participants in the reasons for geographic and racial differences in stroke (REGARDS) cohort study","volume":"17","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2337\/dc10-0676","article-title":"Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial","volume":"34","author":"Azadbakht","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on BP of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet","volume":"344","author":"Sacks","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0220","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1161\/CIR.0000000000000440","article-title":"Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association","volume":"134","author":"Young","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0225","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high BP in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.metabol.2014.10.018","article-title":"Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis","volume":"64","author":"Chen","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0235","series-title":"Behavioral Counseling to Promote a Healthy Lifestyle for Cardiovascular Disease Prevention in Persons With Cardiovascular Risk Factors: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force 2014","author":"Lin","year":"2014"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0240","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jama.1992.03480090061028","article-title":"The effects of nonpharmacologic interventions on BP of persons with high normal levels Results of the Trials of Hypertension Prevention. Phase I","volume":"267","author":"Whelton","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0245","first-page":"2083","article-title":"Effects of comprehensive lifestyle modification on BP control: main results of the PREMIER clinical trial","volume":"289","author":"Appel","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0250","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0255","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different BP-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"BP Lowering Treatment Trialists\u2019 Collaboration","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0260","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0265","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0270","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1524-6175.2002.2041.x","article-title":"Achieving goal BP in patientswith type 2 diabetes: conventional versus fixed-dose combination approaches","volume":"5","author":"Bakris","year":"2003","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0275","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","article-title":"A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial","volume":"53","author":"Feldman","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0280","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","article-title":"Diabetes mellitus as a compelling indication for use of rennin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0285","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0290","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/CIRCULATIONAHA.110.008870","article-title":"BP targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)","volume":"124","author":"Mancia","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0295","doi-asserted-by":"crossref","first-page":"e1001971","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catala-Lopez","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/blo.9.2.17.20","article-title":"Results of the STOP-Hypertension-2 trial","volume":"2","author":"Hansson","year":"2000","journal-title":"Blood Press. Suppl."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0305","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1524-6175.2004.03216.x","article-title":"Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study","volume":"6","author":"Barzilay","year":"2004","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0315","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0320","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/HJH.0b013e32831fb389","article-title":"Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study","volume":"27","author":"Hillebrand","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0325","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.112.194787","article-title":"Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients","volume":"60","author":"Raheja","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0330","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0335","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0340","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000334161","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"33","author":"Bomback","year":"2012","journal-title":"Blood Purif."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0350","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces BP in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0355","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0360","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"BP effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0365","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces BP in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend","year":"2016","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0375","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"BP-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0380","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajh\/hpt196","article-title":"Effect of GLP-1 mimetics on BP and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression","volume":"27","author":"Katout","year":"2014","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0385","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2013"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0390","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","article-title":"Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies","volume":"332","author":"Huxley","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0395","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0021-9681(80)90021-1","article-title":"Sex differences in coronary mortality among diabetics in Evans County, Georgia","volume":"33","author":"Heyden","year":"1980","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0400","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2337\/diacare.23.7.962","article-title":"Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies","volume":"23","author":"Lee","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0405","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00125-014-3260-6","article-title":"Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events","volume":"57","author":"Peters","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0410","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/dc13-1953","article-title":"Increased risk of subsequent myocardial infarction in patients with type 2 diabetes mellitus: a retrospective cohort study using the U.K. General Practice Research Database","volume":"3","author":"Liang","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0415","doi-asserted-by":"crossref","first-page":"R245","DOI":"10.1530\/EJE-14-0401","article-title":"Cardiovascular risk in women with type 2 diabetes mellitus and prediabetes: is it indeed higher than men?","volume":"171","author":"Anagnostis","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1741-7015-11-161","article-title":"Personalizing guidelines for diabetes management: twilight or dawn of the expert?","volume":"11","author":"Paschou","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.maturitas.2018.03.013_bib0425","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.1976.03260470017018","article-title":"Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975","volume":"235","author":"Stamler","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0430","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1111\/j.1753-4887.2004.tb00085.x","article-title":"Prevalence and trends in overweight in Mexican-american adults and children","volume":"62","author":"Flegal","year":"2004","journal-title":"Nutr. Rev."},{"issue":"9438","key":"10.1016\/j.maturitas.2018.03.013_bib0435","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2018.03.013_bib0440","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/ajh.2008.185","article-title":"Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999\u20132004","volume":"21","author":"Gu","year":"2008","journal-title":"Am. J. Hypertens."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218301415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218301415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:12:00Z","timestamp":1759914720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512218301415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":88,"alternative-id":["S0378512218301415"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.03.013","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension in patients with type 2 diabetes mellitus: Targets and management","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}